Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CNAT
  • CUSIP: N/A
  • Web:
  • Market Cap: $155.97 million
  • Outstanding Shares: 26,169,000
Average Prices:
  • 50 Day Moving Avg: $5.69
  • 200 Day Moving Avg: $5.57
  • 52 Week Range: $1.45 - $9.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -66.22
  • P/E Growth: -0.22
Sales & Book Value:
  • Annual Revenue: $7.8 million
  • Price / Sales: 20.00
  • Book Value: $0.74 per share
  • Price / Book: 8.05
  • EBIDTA: ($26,140,000.00)
  • Return on Equity: -107.25%
  • Return on Assets: -45.07%
  • Debt-to-Equity Ratio: 0.65%
  • Current Ratio: 2.39%
  • Quick Ratio: 2.39%
  • Average Volume: 982,964 shs.
  • Beta: 1.29
  • Short Ratio: 3.34
Frequently Asked Questions for Conatus Pharmaceuticals (NASDAQ:CNAT)

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.20. The business earned $7 million during the quarter, compared to analyst estimates of $5.88 million. During the same quarter in the prior year, the company posted ($0.35) EPS. View Conatus Pharmaceuticals' Earnings History.

When will Conatus Pharmaceuticals make its next earnings announcement?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Conatus Pharmaceuticals.

Where is Conatus Pharmaceuticals' stock going? Where will Conatus Pharmaceuticals' stock price be in 2017?

7 analysts have issued 1-year target prices for Conatus Pharmaceuticals' stock. Their predictions range from $7.00 to $26.00. On average, they expect Conatus Pharmaceuticals' share price to reach $14.50 in the next twelve months. View Analyst Ratings for Conatus Pharmaceuticals.

What are analysts saying about Conatus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Conatus presently has no approved product in its portfolio. However, its progress with the lead candidate, emricasan has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Moreover, the stock has outperformed the industry in the last one year. On the flip side, though emricasan is progressing well, it is still several years away from entering the market, if at all. Any development/regulatory setback could hamper Conatus’ prospects. Notably, several companies are working on developing treatments for NASH which might make the market competitive for emricasan. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/24/2017)
  • 2. Aegis analysts commented, "We believe that Novartis will likely exercise its option for worldwide exclusive rights to Emricasan. Potential Combination Products. Under the agreement, Novartis’ option includes the ability to develop products using either Emricasan as the sole active ingredient or in combination with other compounds in its pipeline (e.g., farnesoid X). The tiered royalties payable to Conatus for these potential combination products range from high-single digits to mid-teens and are subject to certain reductions." (3/16/2017)
  • 3. FBR & Co analysts commented, "We think the strong pairing formed when Conatus Pharmaceuticals signed an option, collaboration, and licensing agreement with Novartis (NVS) firmly de-risked the path for completing clinical development of CNAT's Phase III ready liver disease drug emricasan, which is the most clinically advanced drug candidate in liver cirrhosis. In particular, we look for CNAT to benefit from collaborative synergies with NVS's expertise in liver disease research, and its track record of success in drug development and commercialization. As it is now a key new program in NVS's pipeline of $1B-plus potential product candidates, we also think this deal validates the value of emricasan, with the $650M deal recognition of emricasan's potential application in liver diseases with different etiologies. Therefore, we reiterate our Outperform rating." (3/15/2017)

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totalling 2,800,954 shares, an increase of 340.0% from the June 15th total of 636,585 shares. Based on an average daily volume of 1,195,356 shares, the days-to-cover ratio is presently 2.3 days. Currently, 11.3% of the shares of the stock are short sold.

Who are some of Conatus Pharmaceuticals' key competitors?

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:

  • David F. Hale, Independent Chairman of the Board
  • Steven J. Mento Ph.D., President, Chief Executive Officer, Acting Principal Financial Officer, Director
  • Alfred P. Spada Ph.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • David T. Hagerty M.D., Executive Vice President, Clinical Development
  • Daniel L. Ripley, Senior Vice President - Business Development, Program and Alliance Management
  • Edward F. Smith III., Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Michelle L. Vandertie, Acting Principal Accounting Officer
  • Daniel L. Kisner M.D., Additional Independent Director
  • Preston S. Klassen M.D., Additional Independent Director
  • William R. LaRue, Additional Independent Director

Who owns Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (4.20%), Russell Investments Group Ltd. (0.45%), Strs Ohio (0.10%), Reilly Financial Advisors LLC (0.08%) and Bank of Montreal Can (0.07%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

Who bought Conatus Pharmaceuticals stock? Who is buying Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Strs Ohio and Bank of Montreal Can. View Insider Buying and Selling for Conatus Pharmaceuticals.

How do I buy Conatus Pharmaceuticals stock?

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $5.96.

MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (143.29% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/29/2017HC WainwrightReiterated RatingBuy$18.00HighView Rating Details
5/15/2017AegisReiterated RatingBuy$11.00N/AView Rating Details
3/16/2017Stifel NicolausReiterated RatingBuy -> Buy$7.00 -> $9.00HighView Rating Details
3/15/2017FBR & CoReiterated RatingOutperform$16.00HighView Rating Details
12/23/2016SunTrust Banks, Inc.Reiterated RatingBuy$17.00 -> $26.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00N/AView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuy -> BuyN/AView Rating Details
9/24/2015Piper Jaffray CompaniesReiterated RatingHold$5.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Earnings History by Quarter for Conatus Pharmaceuticals (NASDAQ CNAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($0.17)N/AView Earnings Details
5/4/2017Q1 2017($0.34)($0.14)$5.88 million$7.00 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.32)($0.35)$0.80 millionViewN/AView Earnings Details
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.35)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.43)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.39)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.34)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)
2017 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.01)($0.17)
Q2 20173($0.26)$0.00($0.17)
Q3 20172($0.26)($0.01)($0.14)
Q4 20172($0.26)($0.02)($0.14)
(Data provided by Zacks Investment Research)


Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 18.68%
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Conatus Pharmaceuticals (NASDAQ:CNAT)
Latest Headlines for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateHeadline logoWhat's in Store for Conatus (CNAT) this Earnings Season? - Nasdaq - July 26 at 5:55 PM logoWhat's in Store for Conatus (CNAT) this Earnings Season? - July 26 at 5:55 PM logoConatus Pharmaceuticals to Report Second Quarter 2017 Financial Results - July 26 at 5:55 PM logoConatus Pharmaceuticals Inc. (CNAT) Set to Announce Earnings on Tuesday - July 25 at 7:22 AM logoConatus Pharmaceuticals Inc. (CNAT) Upgraded to Hold at Zacks Investment Research - July 24 at 1:36 PM logoConatus Pharmaceuticals Inc (CNAT) Given Average Recommendation of "Buy" by Brokerages - July 18 at 12:13 PM logoConatus Pharmaceuticals Inc. (CNAT) Short Interest Up 340.0% in June - July 14 at 7:34 AM logoConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Cut to "Sell" at Zacks Investment Research - July 11 at 8:28 PM logoHealth Care Sector Update for 07/07/2017: CNAT,NVO,ARNA,DXTR ... - Nasdaq - July 8 at 5:02 PM logoWhy Conatus Pharma Wins With Newest Licensing Agreement - 24/7 Wall St. - July 8 at 5:02 PM logoWhy Conatus Pharma Wins With Newest Licensing Agreement - July 8 at 9:54 AM logoConatus Announces Effectiveness of Exclusive License for Global ... - GlobeNewswire (press release) - July 6 at 11:37 PM logoConatus Pharmaceuticals announces effectiveness of Novartis license - Seeking Alpha - July 6 at 11:37 PM logoConatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment - July 6 at 6:36 PM logo Analysts Anticipate Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Will Post Quarterly Sales of $7.93 Million - July 5 at 10:46 AM logoConatus Pharmaceuticals Inc. (CNAT) Expected to Post Earnings of -$0.09 Per Share - July 3 at 6:30 PM logoH.C. Wainwright Bullish on Conatus Pharmaceuticals Inc (CNAT) on Back of Orphan Drug Designation for IDN-7314 - June 29 at 6:35 PM logoConatus Pharmaceuticals Inc. (CNAT) Stock Rating Reaffirmed by HC Wainwright - June 29 at 7:34 AM logoConatus's PSC Candidate Gets Orphan Designation in the U.S. - June 27 at 4:37 PM logoToday's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals - June 27 at 4:37 PM logoConatus Pharmaceuticals (CNAT) Gains FDA Orphan Drug Designation for IDN-7314 - June 26 at 5:08 PM logoConatus Pharmaceuticals (CNAT) Gains FDA Orphan Drug Designation for IDN-7314 - - June 26 at 7:37 AM logoFDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC - June 26 at 7:37 AM logoConatus Pharmaceuticals Inc. (CNAT) Receives Average Recommendation of "Buy" from Analysts - June 23 at 9:23 AM logoConatus Pharmaceuticals (CNAT) Presents Poster Presentation on Emricasan at International Liver Cell Conference - - June 17 at 9:43 PM logoConatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference - June 16 at 5:09 PM logoShort Interest in Conatus Pharmaceuticals Inc. (CNAT) Decreases By 37.7% - June 13 at 7:04 AM logoConatus Pharmaceuticals Inc (CNAT) Expected to Post Quarterly Sales of $7.93 Million - June 9 at 1:28 PM logoConatus (CNAT) Down 33.1% Since Earnings Report: Can It Rebound? - June 8 at 5:26 PM logo-$0.09 EPS Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter - June 7 at 4:46 PM logoConatus Pharmaceuticals Inc (CNAT) Short Interest Up 33.6% in May - May 28 at 7:12 AM logoConatus Pharmaceuticals Inc (CNAT) Lifted to "Hold" at ValuEngine - May 24 at 3:56 PM logoConatus Pharmaceuticals Inc to Post FY2019 Earnings of $3.72 Per Share, SunTrust Banks Forecasts (CNAT) - May 24 at 2:58 PM logoConatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - May 16 at 4:27 PM logoRevisiting Conatus Pharmaceuticals Due To Recent Pipeline Expansion Talks - May 15 at 6:56 PM logoSunTrust Banks Research Analysts Lower Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT) - May 15 at 9:50 AM logoConatus Pharmaceuticals Inc (CNAT) Expected to Post Quarterly Sales of $7.74 Million - May 13 at 8:00 AM logoToday's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics - May 12 at 4:54 PM logoZacks: Analysts Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Announce Earnings of -$0.09 Per Share - May 11 at 6:28 PM logoConatus Announces Pricing of Public Offering of Common Stock - May 11 at 4:59 PM logoFDA Nod For MRK's Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes - May 11 at 2:38 AM logoConatus Pharmaceuticals (CNAT) Plans Offering of Common Stock - May 11 at 2:38 AM logoConatus Pharmaceuticals (CNAT) Plans Offering of Common Stock - - May 10 at 4:36 PM logoConatus Announces Proposed Public Offering of Common Stock - May 10 at 4:36 PM logoConatus reports 1Q loss - May 5 at 9:39 PM logoConatus Pharmaceuticals' (CNAT) "Buy" Rating Reiterated at Aegis - May 5 at 9:28 AM logoConatus Pharmaceuticals Inc (CNAT) Announces Quarterly Earnings Results - May 4 at 11:32 PM logoConatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates - May 4 at 4:32 PM logoConatus Announces Exercise of License Option for... - May 4 at 5:55 AM logoConatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis - May 4 at 5:55 AM



Conatus Pharmaceuticals (CNAT) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff